ASH 2020 | STAR T-cell therapy for R/R B-cell ALL
Peihua Lu, MD, Beijing Lu Daopei Institute of Hematology, Beijing, China, shares interim findings from the first-in-human Phase I study (NCT03953599) of a double-chain chimeric receptor in pediatric and adult patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). The synthetic T-cell receptor and antigen receptor (STAR) is a novel CD19-targeted double-chain receptor. Compared to conventional CAR, preclinical studies demonstrated STAR T-cells to have improved killing ability, faster and stronger T-cell activation, and higher cytokine production. In the Phase I trial, all 18 patients achieved complete remission (CR) at day 14, with a negative measurable residual disease (MRD) status. Following STAR T-cell infusion, patients who received consolidation allogeneic stem cell transplantation (allo-HSCT) all remain in CR. Of the 10 patients that did not pursue allo-HSCT, 8 remain in CR. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
